

Piramal and Fujifilm Diosynth announce strategic alliance for ADCs

Mumbai, Aug 1, 2012: Piramal Healthcare UK has announced it has entered into a strategic alliance with Fujifilm Diosynth Biotechnologies. The companies will offer seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

The deal will allow customers to benefit from the experience and assets of both organisations, while simplifying supply chain and vendor management relationships, leading to shorter time to clinic.

Through its Grangemouth UK facility, Piramal is a global leader in antibody drug conjugation, while Fujifilm Diosynth Biotechnologies is one of the world's leading providers of contract development and manufacturing services for biopharmaceuticals.

The companies' combined experience covers work on more than 150 biopharmaceuticals and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world's only FDA-approved ADC.

Aidan Walker, President Formulations Services for Piramal said: "We are delighted to combine with Fujifilm Diosynth Biotechnologies to offer a seamless service to customers for the production of antibody conjugates. Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programmes, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients".

Stephen Taylor, Commercial Vice President of Fujifilm Diosynth Biotechnologies said: "This strategic alliance with Piramal is an important step for us in bringing a new, high-technology offering to the market place. Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development. Piramal is a recognised world-leader in this area and we are delighted to be partnering with them".

For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals. The company recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.

The alliance was announced to coincide with late October's ADC World Summit in San Francisco. The sector's leading annual technology event, the Summit was attended by both Piramal and Fujifilm Diosynth



About Piramal Healthcare

Piramal Healthcare is a part of the Piramal Enterprises Ltd. Led by Ajay G. Piramal, the Piramal Group is one of India's foremost business conglomerates. Emerging from a rich textile industry lineage, the Piramal Group has exemplified diversification by foraying into a myriad of industries that encompass healthcare, drug discovery and research, glass, real estate and financial services.

Piramal Enterprises, Piramal Life Sciences, Piramal Glass and Piramal Realty are the flagship companies that operate within these sectors. The Piramal Group truly demonstrates a global footprint with its products and services being exported to over 100 countries, its international income contributing to greater than 70% of the Group's revenues and more than 15 nationalities being represented amongst its employees.